{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:21:46Z","timestamp":1740147706342,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s11739-024-03553-3","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T17:04:34Z","timestamp":1707498274000},"page":"1167-1171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Variability of the anticoagulant effect according to body weight in patients treated with direct oral anticoagulants"],"prefix":"10.1007","volume":"19","author":[{"given":"Lorenzo","family":"Belli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Radico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Auciello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Patti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabina","family":"Gallina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4770-8386","authenticated-orcid":false,"given":"Giulia","family":"Renda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,9]]},"reference":[{"issue":"5","key":"3553_CR1","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C et al (2021) 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 42(5):373\u2013498","journal-title":"Eur Heart J"},{"issue":"10","key":"3553_CR2","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","volume":"23","author":"J Steffel","year":"2021","unstructured":"Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG et al (2021) 2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace 23(10):1612\u20131676","journal-title":"Europace"},{"issue":"11","key":"3553_CR3","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.jacc.2014.05.065","volume":"64","author":"A Cuker","year":"2014","unstructured":"Cuker A, Siegal DM, Crowther MA, Garcia DA (2014) Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 64(11):1128\u20131139","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"3553_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/ehjcvp\/pvw032","volume":"3","author":"T Salmonson","year":"2017","unstructured":"Salmonson T, Dogne JM, Janssen H, Garcia Burgos J, Blake P (2017) Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future: views from a workshop at the European Medicines Agency (EMA). Eur Heart J Cardiovasc Pharmacother 3(1):42\u201347","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"10","key":"3553_CR5","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","volume":"58","author":"W Byon","year":"2019","unstructured":"Byon W, Garonzik S, Boyd RA, Frost CE (2019) Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet 58(10):1265\u20131279","journal-title":"Clin Pharmacokinet"},{"issue":"3\u20134","key":"3553_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.vph.2013.07.003","volume":"59","author":"G Renda","year":"2013","unstructured":"Renda G, De Caterina R (2013) The new oral anticoagulants in atrial fibrillation: once daily or twice daily? Vascul Pharmacol 59(3\u20134):53\u201362","journal-title":"Vascul Pharmacol"},{"issue":"6","key":"3553_CR7","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/bcp.12114","volume":"76","author":"VV Upreti","year":"2013","unstructured":"Upreti VV, Wang J, Barrett YC, Byon W, Boyd RA, Pursley J et al (2013) Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol 76(6):908\u2013916","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"3553_CR8","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/jth.13323","volume":"14","author":"K Martin","year":"2016","unstructured":"Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S (2016) Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost 14(6):1308\u20131313","journal-title":"J Thromb Haemost"},{"issue":"10","key":"3553_CR9","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2165\/11595320-000000000-00000","volume":"50","author":"W Mueck","year":"2011","unstructured":"Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F (2011) Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 50(10):675\u2013686","journal-title":"Clin Pharmacokinet"},{"key":"3553_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ahj.2019.02.001","volume":"212","author":"ED Peterson","year":"2019","unstructured":"Peterson ED, Ashton V, Chen YW, Wu B, Spyropoulos AC (2019) Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation. Am Heart J 212:113\u2013119","journal-title":"Am Heart J"},{"issue":"20","key":"3553_CR11","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1161\/CIRCULATIONAHA.118.037955","volume":"139","author":"SH Hohnloser","year":"2019","unstructured":"Hohnloser SH, Fudim M, Alexander JH, Wojdyla DM, Ezekowitz JA, Hanna M et al (2019) Efficacy and safety of Apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight. Circulation 139(20):2292\u20132300","journal-title":"Circulation"},{"key":"3553_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ijcard.2020.06.010","volume":"318","author":"G Patti","year":"2020","unstructured":"Patti G, Pecen L, Manu MC, Huber K, Rohla M, Renda G et al (2020) Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies. Int J Cardiol 318:67\u201373","journal-title":"Int J Cardiol"},{"issue":"6","key":"3553_CR13","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.3390\/jcm9061633","volume":"9","author":"S Deitelzweig","year":"2020","unstructured":"Deitelzweig S, Keshishian A, Kang A, Dhamane AD, Luo X, Li X et al (2020) Effectiveness and safety of oral anticoagulants among NVAF patients with obesity: Insights from the Aristophanes Study. J Clin Med 9(6):1633","journal-title":"J Clin Med"},{"issue":"5","key":"3553_CR14","doi-asserted-by":"publisher","first-page":"F817","DOI":"10.1152\/ajprenal.2000.278.5.F817","volume":"278","author":"A Chagnac","year":"2000","unstructured":"Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U (2000) Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 278(5):F817\u2013F822","journal-title":"Am J Physiol Renal Physiol"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-024-03553-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-024-03553-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-024-03553-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T19:15:20Z","timestamp":1718824520000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-024-03553-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,9]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["3553"],"URL":"https:\/\/doi.org\/10.1007\/s11739-024-03553-3","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"type":"print","value":"1828-0447"},{"type":"electronic","value":"1970-9366"}],"subject":[],"published":{"date-parts":[[2024,2,9]]},"assertion":[{"value":"3 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the institutional Ethical Committee and was conducted in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Written informed consent was obtained from each patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"L.B, F.R, R.A: None. G.P: speaker\/consultant\/advisory board fee from Abbott, Astra Zeneca, Sanofi, Amgen, Menarini, Bayer, Pfizer, BMS, Daiichi Sankyo, Chiesi, MSD, Boehringer Ingelheim, Servier, Guidotti, Medtronic, Biosensors, Terumo. S.G: None. G.R: speaker\/consultant\/advisory board fee from Astra Zeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, BMS\/Pfizer, Menarini.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}